Medical Marijuana a Success in Israel

By Haaretz

Published January 30, 2012.
  • Print
  • Share Share

More than two-thirds of cancer patients who were prescribed medical marijuana to combat pain are reportedly satisfied with the treatment, according to a comprehensive study conducted for the first time in Israel.

The study - conducted recently at Sheba Medical Center, Tel Hashomer, in conjunction with the Israel Cancer Association - involved 264 cancer patients who were treated with medical marijuana for a full year.

Some 61 percent of the respondents reported a significant improvement in their quality of life as a result of the medical marijuana, while 56 percent noted an improvement in their ability to manage pain. In general, 67 percent were in favor of the treatment, while 65 percent said they would recommend it to other patients.

The findings were presented earlier this month at an Israeli Oncologists Union conference in Eilat. The study was led by Dr. Ido Wolf, the director of oncology at the Sheba Cancer Center, with the assistance of researchers Yasmin Leshem, Damien Urbach, Adato Berliz, Tamar Ben Ephraim and Meital Gerty.

According to the study, the most common types of cancer for which medical marijuana is prescribed are lung cancer (21 percent ), breast cancer (12 percent ) and pancreatic cancer (10 percent ).

Researchers found that an average of 325 days passed between the time that patients were diagnosed with cancer and the time that they submitted permit requests to grow or possess medical marijuana. About 81 percent of those requests cited pain resulting from the illness. Some 8 percent of patients requested medical marijuana to combat nausea, while another 8 percent complained of weakness.

For more, go to Haaretz.com


The Jewish Daily Forward welcomes reader comments in order to promote thoughtful discussion on issues of importance to the Jewish community. In the interest of maintaining a civil forum, The Jewish Daily Forwardrequires that all commenters be appropriately respectful toward our writers, other commenters and the subjects of the articles. Vigorous debate and reasoned critique are welcome; name-calling and personal invective are not. While we generally do not seek to edit or actively moderate comments, our spam filter prevents most links and certain key words from being posted and The Jewish Daily Forward reserves the right to remove comments for any reason.





Find us on Facebook!
  • "You wouldn’t send someone for a math test without teaching them math." Why is sex ed still so taboo among religious Jews?
  • Russia's playing the "Jew card"...again.
  • "Israel should deal with this discrimination against Americans on its own merits... not simply as a bargaining chip for easy entry to the U.S." Do you agree?
  • For Moroccan Jews, the end of Passover means Mimouna. Terbhou ou Tse'dou! (good luck) How do you celebrate?
  • Calling all Marx Brothers fans!
  • What's it like to run the Palestine International Marathon as a Jew?
  • Does Israel have a racism problem?
  • This 007 hates guns, drives a Prius, and oh yeah — goes to shul with Scarlett Johansson's dad.
  • Meet Alvin Wong. He's the happiest man in America — and an observant Jew. The key to happiness? "Humility."
  • "My first bra was a training bra, a sports bra that gave the illusion of a flat chest."
  • "If the people of Rwanda can heal their broken hearts and accept the Other as human, so can we."
  • Aribert Heim, the "Butcher of Mauthausen," died a free man. How did he escape justice?
  • This guy skipped out on seder at his mom's and won a $1 million in a poker tournament. Worth it?
  • Sigal Samuel's family amulet isn't just rumored to have magical powers. It's also a symbol of how Jewish and Indian rituals became intertwined over the centuries. http://jd.fo/a3BvD Only three days left to submit! Tell us the story of your family's Jewish heirloom.
  • British Jews are having their 'Open Hillel' moment. Do you think Israel advocacy on campus runs the risk of excluding some Jewish students?
  • from-cache

Would you like to receive updates about new stories?




















We will not share your e-mail address or other personal information.

Already subscribed? Manage your subscription.